David Kennedy - 02 Feb 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Role
General Counsel & Secretary
Signature
/s/ David Kennedy
Issuer symbol
N/A
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 18:32:07 UTC
Next filing
08 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +235,992 235,992 02 Feb 2022 Common Stock 235,992 $1.23 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +3,693 3,693 02 Feb 2022 Common Stock 3,693 $1.23 Direct F2, F3
transaction GRNA Stock Option (Right to Buy) Award +66,560 66,560 02 Feb 2022 Common Stock 66,560 $2.61 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested or shall vest on July 17, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting August 17, 2021.
F2 This option was issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F3 25% of the shares underlying the option vested on July 17, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting August 17, 2021.
F4 25% of the shares underlying the option vested or shall vest on June 30, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting July 30, 2022.